chlorzoxazone has been researched along with Disorders of Excessive Somnolence in 1 studies
Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.
Disorders of Excessive Somnolence: Disorders characterized by hypersomnolence during normal waking hours that may impair cognitive functioning. Subtypes include primary hypersomnia disorders (e.g., IDIOPATHIC HYPERSOMNOLENCE; NARCOLEPSY; and KLEINE-LEVIN SYNDROME) and secondary hypersomnia disorders where excessive somnolence can be attributed to a known cause (e.g., drug affect, MENTAL DISORDERS, and SLEEP APNEA SYNDROME). (From J Neurol Sci 1998 Jan 8;153(2):192-202; Thorpy, Principles and Practice of Sleep Medicine, 2nd ed, p320)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lasofoxifene was tested in 18 postmenopausal women with probe drugs for CYP2E1 and CYP2D6." | 2.72 | Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism. ( Fisher, JM; Gardner, MJ; Kolluri, S; Moller, RA; Obach, RS; Taylor, AE; Walsky, RL, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moller, RA | 1 |
| Fisher, JM | 1 |
| Taylor, AE | 1 |
| Kolluri, S | 1 |
| Gardner, MJ | 1 |
| Obach, RS | 1 |
| Walsky, RL | 1 |
1 trial available for chlorzoxazone and Disorders of Excessive Somnolence
| Article | Year |
|---|---|
Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism.
Topics: Administration, Oral; Chlorzoxazone; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cy | 2006 |